medigraphic.com
ISSN 2992-779X (Digital)
ISSN 2007-6452 (Impreso)

2025, Número 3

Siguiente >>

Investigación en Discapacidad 2025; 11 (3)


Analysis of the giant cell tumor cell line of bone TIB 223 on the effect of quercetin

Monroy QDL, Luna AAB, Aguilar GMR, Santamaría OMG, Hidalgo-Bravo A, Sánchez CL,Estrada VEG, Couder GBC, Landa SC

Idioma: Ingles.
Referencias bibliográficas: 36
Paginas: 84-93
Archivo PDF: 1490.20 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kennel KB, Bozlar M, De Valk AF, Greten FR. Cancerassociatedfibroblasts in inflammation and antitumorimmunity. Clin Cancer Res. 2023; 29 (6): 1009-1016.

  2. Sánchez-Torres LJ, Santos-Hernández M. [The art ofdiagnosing bone tumors]. Acta Ortop Mex. 2012; 26 (1):57-65.

  3. Latorre MR, Albergo JI, Farfalli GL, Roitman PD, PlantalechL, Ayerza MA et al. Denosumab como tratamientoneoadyuvante del tumor de células gigantes del hueso.Indicaciones, resultados y efectos adversos [Denosumab asa treatment for giant cell tumor of bone. Indications, resultsand side effects]. Medicina (B Aires). 2021; 81 (5): 767-773.

  4. Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N,Pinto L et al. Bone metastases: an overview. Oncol Rev.2017; 11 (1): 321.

  5. Coleman RE. Clinical features of metastatic bonedisease and risk of skeletal morbidity. Clin Cancer Res.2006; 12 (20 Pt 2): 6243s-6249s.

  6. Qian Y, Song X, Zhang K, Balakumaran A, Arellano J.Short-term disability in solid tumor patients with bonemetastases and skeletal-related events. J Med Econ.2015; 18 (3): 210-218.

  7. Hile ES, Fitzgerald GK, Studenski SA. Persistent mobilitydisability after neurotoxic chemotherapy. Phys Ther.2010; 90 (11): 1649-1657.

  8. Park SB, Goldstein D, Krishnan AV, Lin CS, FriedlanderML, Cassidy J et al. Chemotherapy-induced peripheralneurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63 (6): 419-437.

  9. Castaneda M, den Hollander P, Kuburich NA, RosenJM, Mani SA. Mechanisms of cancer metastasis. SeminCancer Biol. 2022; 87: 17-31.

  10. Hashemzaei M, Delarami Far A, Yari A, HeraviRE, Tabrizian K, Taghdisi SM et al. Anticancer andapoptosis‑inducing effects of quercetin in vitro and invivo. Oncol Rep. 2017; 38 (2): 819-828.

  11. Riaz MK, Zhang X, Wong KH, Chen H, Liu Q, Chen X etal. Pulmonary delivery of transferrin receptors targetingpeptide surface-functionalized liposomes augments thechemotherapeutic effect of quercetin in lung cancertherapy. Int J Nanomedicine. 2019; 14: 2879-2902.

  12. Marure-Rojano AE, Cano-García JR, Luna-Agulo AB,Sánchez-Chapul L, Santos-Cuevas CL, Aguilar-GaytánMDR et al. The cytotoxic effect of quercetin-inducedapoptosis on lung metastatic cells from giant cell tumor ofbone. Cell Mol Biol (Noisy-le-grand). 2025; 71 (5): 6-12.

  13. Reyes-Farias M, Carrasco-Pozo C. The Anti-cancereffect of quercetin: molecular implications in cancermetabolism. Int J Mol Sci. 2019; 20 (13): 3177.

  14. Valdespino-Gómez VM, Valdespino-Castillo PM,Valdespino-Castillo VE. Interacción de las víasde señalización intracelulares participantes en laproliferación celular: potencial blanco de intervencionismoterapéutico [Cell signaling pathways interaction incellular proliferation: Potential target for therapeuticinterventionism]. Cir Cir. 2015; 83 (2): 165-174.

  15. López-Oliva E. Efecto de flavonoides de origen vegetalsobre la vía del NO/GMPC. [Tesis de Maestría].Universidad Juárez Autónoma de Tabasco. 2024.

  16. Cao X, He Y, Li X, Xu Y, Liu X. The IRE1α-XBP1pathway function in hypoxia-induced pulmonary vascularremodeling, is upregulated by quercetin, inhibitsapoptosis and partially reverses the effect of quercetinin PASMCs. Am J Transl Res. 2019; 11 (2): 641-654.

  17. González-Magaña A, Blanco FJ. Human PCNAstructure, function, and interactions. Biomolecules.2020; 10 (4): 570.

  18. Espinoza-Laparra M. Determinación del efecto deCalendula officinalis sobre los niveles de expresión demarcadores tumorales en cáncer de pulmón. [Tesis deMaestría]. Instituto Politécnico Nacional. 2011.

  19. Qiu X, Wang H, Wang Z, Fu Y, Yin J. Expression ofPCNA, Ki-67 and COX-2 in breast cancer based onDCE-MRI image information. J Infect Public Health.

  20. 2020; 13 (12): 2032-2037.20. Yang C, Song J, Park S, Ham J, Park W, Park H etal. Targeting thymidylate synthase and tRNA-derivednon-coding RNAs improves therapeutic sensitivity incolorectal cancer. Antioxidants (Basel). 2022; 11 (11):

  21. 2158.21. Yadav N, Tripathi AK, Parveen A, Parveen S, BanerjeeM. PLGA-quercetin nano-formulation inhibits cancerprogression via mitochondrial dependent caspase-3,7 and independent FoxO1 activation with concomitantPI3K/AKT suppression. Pharmaceutics. 2022; 14 (7):1326.

  22. Muñoz MM, Saavedra BA. Efectos anticancerígenosde los flavonoides quercetina y luteolina, con enfoqueen el cáncer de ovario: Universidad de Talca (Chile).Escuela de Tecnología Médica.; 2020.

  23. Elinos-Báez CM, Maldonado V, Zajgla JM. Caspasas:moléculas inductoras de apoptosis. Gac Méd México.2003; 139 (5): 493-499.

  24. Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K et al.The role of necroptosis in cancer biology and therapy.Mol Cancer. 2019; 18 (1): 100.

  25. Ju E, Park KA, Shen HM, Hur GM. The resurrectionof RIP kinase 1 as an early cell death checkpointregulator-a potential target for therapy in the necroptosisera. Exp Mol Med. 2022; 54 (9): 1401-1411.

  26. García-Aguiar JI. Caracterización del complejo asociadoal receptor 1 del factor de necrosis tumoral en doslíneas celulares HPV-16+ con resistencia diferencial ala apoptosis. [Tesis] 2018.

  27. DeRoo E, Zhou T, Liu B. The role of RIPK1 and RIPK3 incardiovascular disease. Int J Mol Sci. 2020; 21 (21): 8174.

  28. Degterev A, Ofengeim D, Yuan J. Targeting RIPK1 forthe treatment of human diseases. Proc Natl Acad SciUSA. 2019; 116 (20): 9714-9722.

  29. Martínez-Ezquerro JD, Herrera LA. Angiogénesis:VEGF/VEGFRs como blancos terapéuticos en eltratamiento contra el cáncer. Cancerología. 2006; 1 (1):83-96.

  30. Saavedra Garrido P. Resveratrol como coadyuvante enel tratamiento del cáncer. [Tesis] 2016.

  31. Clézardin P, Coleman R, Puppo M, Ottewell P, BonnelyeE, Paycha F et al. Bone metastasis: mechanisms,therapies, and biomarkers. Physiol Rev. 2021; 101 (3):797-855.

  32. Nguyen MV, Carlier C, Nich C, Gouin F, Crenn V.Fracture risk of long bone metastases: a review ofcurrent and new decision-making tools for prophylacticsurgery. Cancers (Basel). 2021; 13 (15): 3662.

  33. Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B,Abrams G et al. Chemotherapy-induced neuropathy incancer survivors. J Pain Symptom Manage. 2017; 54(2): 204-218.e2.

  34. McNeish BL, Dittus K, Mossburg J, Krant N, SteinharterJA, Feb K et al. The association of chemotherapyinducedperipheral neuropathy with reduced executivefunction in chemotherapy-treated cancer survivors: across-sectional study. J Geriatr Oncol. 2024; 15 (4):101765.

  35. Cao C, Yang L, Schmitz KH, Ligibel JA. Prevalence andcancer-specific patterns of functional disability amongus cancer survivors, 2017-2022. J Clin Oncol. 2024; 42(19): 2257-2270.

  36. Cheville AL, Murthy NS, Basford JR, Rose PS, Tran K,Pittelkow TP et al. Imaging and clinical characteristicspredict near-term disablement from bone metastases:implications for rehabilitation. Arch Phys Med Rehabil.2016; 97 (1): 53-60.




2020     |     www.medigraphic.com